Taysha Gene Therapies, Inc. Non Peo Neo Avg Comp Actually Paid Amt
Taysha Gene Therapies, Inc. (TSHA) reported Non Peo Neo Avg Comp Actually Paid Amt of $9.42 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-22.
Financial Statements › Cash Flow › Other Cash Flow Items
ecd:NonPeoNeoAvgCompActuallyPaidAmt · last filed 2026-04-22
| Period end | Non Peo Neo Avg Comp Actually Paid Amt 12 month |
|---|---|
| 2025-12-31 | $9.42M DEF 14A · filed 2026-04-22 |
| 2024-12-31 | $3.03M DEF 14A · filed 2026-04-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |